BioSpace News Archive

MindMed Further Expands R&D Collaboration with University Hospital Basel’s Liechti Lab with Plans To Develop Next-Gen Psychedelic Therapies Combining LSD and MDMA

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced the European launch of the company’s first Extended Depth of Focus intraocular lens, LuxSmart™, and a new monofocal IOL, LuxGood™.

Proprietary tissue-targeted complement platform and best-in-class IL-7R antibody technology to treat patients with severe autoimmune and inflammatory disease; clinical trials begin in 2020

ESSA Pharma Inc., a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Jefferies Virtual Healthcare Conference on Thursday June 4, 2020 at 3:30pm Eastern.

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced that management will participate in fireside chats at the following virtual investor conferences in June:

Alucent Biomedical Inc . announced that it has enrolled the first two patients in ACTIVATE I, a Phase 1 clinical trial to evaluate the safety and efficacy of its revolutionary Natural Vascular Scaffolding (NVS) technology . The therapy is designed to open vessels and keep them open without the use of permanent implants in the treatment of periphe

Virna Therapeutics announces that they are partnering with University of Toronto to in-license neutralizing antibodies, to treat COVID-19.

Jennewein Biotechnologie GmbH announces the publication of the latest results from its norovirus research program in the Journal of Biotechnology.

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced plans for a clinical study intended to support registration in the U.S. of flotetuzumab, an investigational, bispecific CD123 x CD3 DART® molecule for patients with acute myeloid leukemia (AML) who are refractory to induction therapy. In

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today provided an update on the preclinical results f